FewerJobs.

Perspective Therapeutics Inc jobs

76 matches, filter-driven and evidence-linked.

Reset
Showing 76 high-confidence listings. 0 additional listings are hidden by default. Show all
24 shown of 76

Benefit evidence

Resolvable source Inferred from posting Unknown provenance
Only verified benefits
  • Medical Director

    Perspective Therapeutics Inc - Location not specified
    Indexed from Jazzhr
    posted 153 days ago

    Why we showed this

    Description: "perspective"Description: "inc"
    +6
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity

    Medical Director Objective Reporting to the Chief Medical Officer, the Medical Director will lead clinical development strategy and clinical operations for active programs. Duties will include management of cross-functional, multidisciplinary study teams, and oversight for the design and execution of clinical trials. S/he will serve as the Medical Lead and primary Medical Monitor for clinical trials. The Medical Director will work closely with all matrixes of the team including scientists in discovery research, clinical operations, and regulatory affairs. The Medical Director will also participate in advisory meetings with opinion leaders and academic study investigators and will support interactions with Health Authorities. Essential Functions Lead the development of study protocols, statistical analysis plans, investigators brochures, and other key study documents in conjunction with Perspective Leadership and key advisors. Prepare the clinical development plans with support from cross functional team members. Perform regular data reviews (including e.g. PK, safety, efficacy). Provide leadership on cross-functional study teams for assigned trials, working with other team members to achieve efficient, high-quality study execution and data analysis. Participate in the preparation of regulatory documents in support of regulatory submissions, including clinical section of INDs and CTAs, safety reports, responses to regulatory authorities, clinical study reports, and other documents as appropriate, and interface with regulatory authorities as needed. Communicate with and inspire key external stakeholders to facilitate the development and medical oversight of Perspective compounds. Stakeholders and mechanisms of outreach may include: Investigators, Medical Community (e.g., KOLs) Preparation and presentation of abstracts/oral presentations at conferences, and writing

  • Director, Portfolio Strategy

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    2w ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Other - Director Plus From the posting source $190K-$237K From the posting source Equity

    Director, Portfolio Strategy Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

  • Corporate Counsel, Clinical Contracts

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 42 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Legal From the posting source - Mid From the posting source $158K-$185K From the posting source Equity

    Corporate Counsel, Clinical Contracts Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

  • Engineer, Device Development

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    4w ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +5
    Unspecified Other - Mid From the posting source Salary not disclosed Equity

    Engineer, Device Development Viking Therapeutics, Inc. The Engineer of Device Development combines hands-on technical execution with ownership of the integrated devi

  • Associate Director, Site Alliances and Strategy

    Indexed from Greenhouse Comp disclosed in posting
    posted 31 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Other - Director Plus From the posting source $169K-$198K From the posting source Equity

    Associate Director, Site Alliances and Strategy Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

  • Clinical Trial Associate

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    3w ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +5
    Unspecified Healthcare From the posting source - Mid From the posting source Salary not disclosed Equity

    Clinical Trial Associate Viking Therapeutics, Inc. The Clinical Trial Associate (CTA) will provide administrative support to the Clinical Operations Team in full

  • Senior Director, Regulatory Affairs

    Summit Therapeutics - (Remote US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 95 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Legal From the posting source - Director Plus From the posting source $203K-$253K From the posting source Equity

    Senior Director, Regulatory Affairs (Remote US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

  • Program Manager, CMC

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    posted 30 days ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +5
    Unspecified Operations From the posting source - Mid From the posting source Salary not disclosed Equity

    Program Manager, CMC Viking Therapeutics, Inc. As Program Manager, CMC, you will drive the coordinated execution of Chemistry, Manufacturing, and Controls (C

  • Senior Corporate Counsel, Corporate and Securities

    Beam Therapeutics Inc - Cambridge, MA
    Indexed from Greenhouse Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 56 days ago

    Why we showed this

    Description: "therapeutics"Description: "perspective"
    +4
    Unspecified Legal From the posting source - Senior From the posting source $260K-$320K From the posting source Equity Inferred from posting 401(k) reported

    Senior Corporate Counsel, Corporate and Securities Cambridge, MA Company Overview: Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Position Overview: Beam is seeking a talented and experienced Senior Corporate Counsel, Corporate and Securities to join our growing legal team. This is a rare opportunity: a senior legal role with genuine breadth at a company where your judgment, perspective, and voice will have a meaningful impact. Reporting to the Senior Vice President, Legal Affairs, you will structure and negotiate the collaborations and licensing transactions that advance our pipeline, take a leading role in SEC reporting and corporate governance for a public company, and advise senior leadership directly. You will partner closely with business development, alliance management, finance, investor relations, and human resources, and manage outside counsel to help support Beam's continued growth and evolution as it

  • Sr. Manager, Clinical Quality Assurance

    Indexed from Greenhouse Comp disclosed in posting
    posted 72 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Healthcare From the posting source - Senior From the posting source $158K-$185K From the posting source Equity

    Sr. Manager, Clinical Quality Assurance Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

  • Director, Regulatory Affairs

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    posted 88 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +5
    Unspecified Legal From the posting source - Director Plus From the posting source Salary not disclosed Equity

    Director, Regulatory Affairs Viking Therapeutics, Inc. The Director of Regulatory Affairs (RA Director) will manage, evaluate, and execute regulatory projects consis

  • Associate Director, Regulatory Affairs

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 73 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Legal From the posting source - Director Plus From the posting source $168K-$198K From the posting source Equity

    Associate Director, Regulatory Affairs Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

  • Senior Director, Program Management

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    posted 56 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +5
    Unspecified Other - Director Plus From the posting source Salary not disclosed Equity

    Senior Director, Program Management Viking Therapeutics, Inc. As the Senior Director of Program Management at Viking, your primary responsibility will be to drive the plann

  • Associate Medical Director

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    posted 51 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +5
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity

    Associate Medical Director Viking Therapeutics, Inc. The Associate Medical Director, Clinical Development supports medical direction, management, and review of cli

  • Director, Clinical Quality

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    4w ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +5
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity

    Director, Clinical Quality Viking Therapeutics, Inc. The Director, Clinical Quality will lead the Clinical Quality Assurance function and provide strategic leaders

  • posted 48 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +5
    Unspecified Other - Director Plus From the posting source Salary not disclosed Equity

    Director/Senior Director, Preclinical Pharmacology/Toxicology Viking Therapeutics, Inc. Viking Therapeutics is seeking an experienced and highly motivated Director or Senior Director, Preclinical Ph

  • Director, Clinical Operations Analytics & Performance Excellence

    Indexed from Greenhouse Comp disclosed in posting
    posted 38 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Data From the posting source - Director Plus From the posting source $190K-$237K From the posting source Equity

    Director, Clinical Operations Analytics & Performance Excellence Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

  • Director, Biostatistics

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 247 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Data From the posting source - Director Plus From the posting source $203K-$253K From the posting source Equity

    Director, Biostatistics Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy

  • Director, Strategic Analytics and Market Research

    Summit Therapeutics - Princeton, NJ
    Indexed from Greenhouse Comp disclosed in posting
    2 days ago

    Why we showed this

    Employer: semantic matchEmployer: "therapeutics"
    +3
    Unspecified Data From the posting source - Staff Plus From the posting source $203K-$253K From the posting source Equity

    Director, Strategic Analytics and Market Research Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

  • Regional Medical Science Director (Northeast)

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 86 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Healthcare From the posting source - Director Plus From the posting source $200K-$235K From the posting source Equity

    Regional Medical Science Director (Northeast) Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

  • Senior Director, Artificial Intelligence

    Summit Therapeutics - Palo Alto, California, United States, Princeton, New Jersey, United States
    Indexed from Greenhouse Comp disclosed in posting
    posted 108 days ago

    Why we showed this

    Employer: semantic matchEmployer: "therapeutics"
    +3
    Unspecified Other - Director Plus From the posting source $217K-$271K From the posting source Equity

    Senior Director, Artificial Intelligence Palo Alto, California, United States, Princeton, New Jersey, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy

  • Director, Sourcing & Procurement - R&D Clinical Operations and Supplies

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 37 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Remote From the posting source Operations From the posting source - Director Plus From the posting source $190K-$237K From the posting source Equity

    Director, Sourcing & Procurement - R&D Clinical Operations and Supplies Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with

  • Medical Writer, Medical Communications & Publications

    Summit Therapeutics - Palo Alto, California, United States
    Indexed from Greenhouse Comp disclosed in posting
    3w ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Unspecified Healthcare From the posting source - Mid From the posting source $145K-$185K From the posting source Equity

    Medical Writer, Medical Communications & Publications Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

  • Senior Director, Clinical Development, Asia Pacific Lead, Rare Disease Therapeutic Area

    Ipsen - Shanghai
    Indexed from Workday Benefit evidence checked Nov 20, 2026
    5 days ago

    Why we showed this

    Description: "perspective"Description: "inc"
    +2
    Unspecified Healthcare From the posting source - Staff Plus From the posting source Salary not disclosed Inferred from posting 401(k) reported

    Senior Director, Clinical Development, Asia Pacific Lead, Rare Disease Therapeutic Area Shanghai Title: Senior Director, Clinical Development, Asia Pacific Lead, Rare Disease Therapeutic Area Company: Ipsen (shanghai) innovation pharmaceutical Co., Ltd. About Ipsen: Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Supported by nearly 100 years of development experience, with global hubs in the U.S., France and the U.K, we tackle areas of high unmet medical need through research and innovation. Our passionate teams in more than 40 countries are focused on what matters and endeavor every day to bring medicines to patients in 88 countries. We build a workplace that champions human-centric leadership and fosters a culture of collaboration, excellence and impact. At Ipsen, every individual is empowered to be their true selves, grow and thrive alongside the company's success. Join us on our journey towards sustainable growth, creating real impact on patients and society! For more information, visit us at https://www.ipsen.com/ and follow our latest news on LinkedIn and Instagram . Job Description: The Senior Director, Clinical Development, Asia Pacific Lead, Rare Disease Therapeutic Area is the regional clinical development leader for Ipsen's Rare Disease portfolio across Asia Pacific. The role is responsible for translating global clinical development strategy into effective regional plans and execution, while ensuring that Asia-Pacific scientific, clinical, regulatory, operational and patient perspectives are incorporated into global development decisions. Based in Shanghai, the role will work in close partnership with the

Take this list with you

Download the 76 matching jobs in any format - read offline, archive, or hand to an AI assistant with your resume to find the best fits.

Or email it to me instead

The AI-ready prompt is a pre-written question you can paste into Claude, ChatGPT, Gemini, or Perplexity along with your resume. We never see your resume; this happens in your AI client of choice.

AI agent reading directly? Same data lives at /api/jobs.json?q=Perspective+Therapeutics+Inc. See /llms.txt and /api/openapi.json for the full schema.